CompletedPhase 2NCT00584194
Safety and Immunogenicity Study of Rift Valley Fever Vaccine
Studying Coccidioidomycosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- U.S. Army Medical Research and Development Command
- Principal Investigator
- Janice Rusnak, MDUSAMRIID Medical Division
- Intervention
- TSI-GSD 200 RVF Vaccine(biological)
- Enrollment
- 278 enrolled
- Eligibility
- 17 years · All sexes
- Timeline
- 2004 – 2010
Study locations (1)
- U.S. Army Medical Research Institute of Infectious Diseases, Fort Deterick, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00584194 on ClinicalTrials.govOther trials for Coccidioidomycosis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT06799234Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)University of Oxford
- ACTIVE NOT RECRUITINGPHASE1NCT06925919Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011IDBiologics, Inc.
- ACTIVE NOT RECRUITINGNANCT06913803To Find Effectiveness of Stretching Versus Soft Tissue Mobilization in Coccydynia in Postpartum FemalesSuperior University
- RECRUITINGPHASE2NCT03609398Phase 2 Safety and Immunogenicity Study of Rift Valley Fever VaccineU.S. Army Medical Research and Development Command
- RECRUITINGNCT02190266Pathogenesis and Genetics of Disseminated or Refractory CoccidioidomycosisNational Institute of Allergy and Infectious Diseases (NIAID)